Overview

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Status:
Completed

Trial end date:
2014-09-01

Target enrollment:

Participant gender:

Summary

The objectives of the study are to evaluate the safety, tolerability and efficacy of AVP-923 compared to placebo, for the treatment of symptoms of agitation in patients with Alzheimer's Disease (AD).

Phase:

Phase 2

Details

Lead Sponsor:

Avanir Pharmaceuticals

Treatments:

Dextromethorphan
Quinidine
Quinidine gluconate